About: Radiopharm Theranostics Limited a clinical-stage radiotherapeutics company, engages in the development of radiopharmaceutical products for diagnostic and therapeutic uses in areas with high unmet medical needs. The company develops RAD101, a pivalate brain metastasis diagnostic; RAD102, a pivalate therapeutic; RAD201a, a Nano-mAb HER-2 breast diagnostic; RAD202, a Nano-mAb HER-2 breast therapeutic; RAD203, a Nano-mAb PDL1 non-small cell lung diagnostic; and RAD204, a Nano-mAb PDL1 non-small cell lung therapeutic. It is also developing RAD301 and RAD302, which are Avß6-Integrin pancreatic diagnostic and therapeutic products; RAD401, a PSA-mAb prostate cancer diagnostic; and RAD402, a PSA-mAb prostate cancer therapeutic. The company was incorporated in 2021 and is based in Carlton, Australia.
Sector: Healthcare
Industry: Biotechnology
Latest price: A$0.01 (-9.09%)
RAD ASX Radiopharm Theranostics Ltd
Radiopharm Theranostics Ltd share price
RAD price activity
Last Price
$0.010
Change (24hr)
-0.00 AUD (-9.09%)
Volume
1.78M
Volume (4w avg)
-
Open
$0.01
Day Range
$0.01 - $0.01
Previous Close
$0.01
Last Trade
08 Oct, 5:10 am GMT+0
Delayed
08 Oct, 5:10 am GMT+0
RAD price performance
Delayed
08 Oct, 5:10 am GMT+0
RAD Market Signals